Stifel raises Rhythm Pharmaceuticals stock price target on launch By Investing.com

Stifel raised Rhythm Pharmaceuticals' price target to $133 from $131 and kept a Buy rating, citing a solid early launch in acquired hypothalamic obesity, with more than 150 start forms from about 110 unique prescribers in the first six weeks. Rhythm also reported Q1 2026 revenue of $60.1 million, above the $55.62 million consensus, while EPS of -$0.83 matched expectations. Shares remain pressured, down 20% year-to-date and 14% over six months, though still up 33% over the past year.

Analysis

RYTM’s setup is less about a single quarter and more about whether the launch can avoid the classic orphan-drug deceleration that follows the initial prescriber burst. The key second-order signal is the breadth of first-wave prescribers: if that cohort converts into repeat ordering, the revenue curve can stay convex for several quarters; if not, the stock likely remains trapped in the skepticism band even on clean beats. In other words, the debate is shifting from “does the drug work?” to “does the field force meaningful patient capture through routine endocrinology workflows?”

The market is also underestimating how much of this story is a sentiment/positioning trade versus a pure fundamentals trade. A mildly positive launch with improving ex-U.S. contribution can support multiple expansion, but the upside is capped if investors continue to model the obesity TAM conservatively and treat the next PWS readout as binary-risk far in the future. That creates an awkward asymmetry: good execution can grind the stock higher, but any evidence of prescriber dropout or slower new-start conversion would likely compress the multiple quickly because expectations are already anchored by recent weakness.

The contrarian angle is that consensus may be too focused on absolute TAM size and not enough on channel efficiency. For a specialty therapy, the first 60-90 days are often noise; the real tell is whether patient starts normalize after routine follow-up cycles. If management sustains launch breadth into the back half of the year, the rerating could be driven more by confidence in duration of demand than by headline patient counts alone.

Key Decisions for Investors

• Long RYTM on pullbacks over the next 2-6 weeks; use weakness toward recent support to build a position, targeting a 15-25% upside rerate if launch momentum remains broad and durable.
• Buy RYTM call spreads 3-6 months out to express upside with defined risk; prefer structures that monetize a grind-higher rather than a sharp break above current levels.
• Pair trade: long RYTM / short a basket of crowded obesity-duration names if you want to isolate launch execution versus broad biotech sentiment; this reduces beta while keeping exposure to launch confirmation.
• If already long, trim 20-30% into strength ahead of any data lull and re-add only if weekly prescription flow does not decelerate over the next 1-2 months.
• Avoid adding outright size before evidence of repeat patient starts; the main downside catalyst is not a missed quarter, but a visible step-down in new-start cadence after the initial prescriber enthusiasm fades.